In the present work, we hypothesized that adding CANA, an SGLT2 inhibitor developed for the treatment of hyperglycemia in T2DM, to storage solution (physiological saline), protects the vascular grafts of nondiabetic rats against IRI. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.